Synlait Milk was New Zealand’s dairy growth story of the 2010s: a Canterbury processor making infant formula for a2 Milk. It then borrowed heavily for a second plant it never filled, lost its biggest customer’s exclusivity and came close to insolvency. A 2024 recapitalisation lifted Bright Dairy’s stake to 65.25%; in April 2026 the North Island assets were sold to Abbott for NZ$307 million. FY26 still ended with a NZ$75.4 million loss, though the second half was profitable.
Synlait Milk is a cautionary tale about what debt-funded expansion does to a manufacturer that depends on a single customer. This article explains how Synlait was founded, how it earns money as a processor of other companies’ brands, how Bright Dairy and a2 Milk came to own most of it, which decisions led to the 2024 rescue, what the sale to Abbott achieved, what the FY26 numbers show and whether the recovery under way at Dunsandel is durable. It is part of the New Zealand Company Stories hub.
What went wrong at Synlait?
It built and bought capacity with debt, including a NZ$180 million retail bond, on the assumption that infant-formula demand would keep rising. When its main customer’s volumes fell after 2020, the fixed costs and interest remained.
Who rescued it?
Bright Dairy of Shanghai, a shareholder since 2010, provided a NZ$130 million loan and NZ$185 million of new equity in 2024. The a2 Milk Company invested NZ$32.8 million to keep its 19.8% holding.
Where does it stand now?
After the Abbott sale, net debt fell to NZ$215 million at 31 July 2026. FY26 revenue was NZ$1.94 billion with an underlying EBITDA of NZ$46.3 million; a permanent chief executive has yet to be named.
How did Synlait start?
Synlait began in 2000 as a large-scale dairy-farming venture on the Canterbury Plains, founded by John Penno, Ben Dingle and Juliet Maclean. It moved into processing in 2008, when its first milk-powder dryer opened at Dunsandel, south of Christchurch.
The founders’ insight was that irrigated Canterbury farms could produce milk to a customer’s specification, and that an independent processor could be paid for that tailoring. The slogan was “making more from milk”: instead of standard powders, Synlait would make ingredients designed for particular multinational customers, with milk from farms paid premiums for meeting defined standards.
Building a plant during the global financial crisis nearly finished the company before it started. A planned share float was abandoned, and in 2010 Bright Dairy, a listed food company controlled by Shanghai’s municipal government, paid about NZ$82 million for 51% of the processing business. Synlait listed on the NZX in July 2013 at NZ$2.20 a share, reducing Bright to 39%, and later added an ASX listing.
From the outset Synlait defined itself against the incumbent described in the Fonterra story: farmers did not have to buy shares to supply it, and it promised to be faster and closer to customers.
How does Synlait make money?
Synlait buys milk from contracted Canterbury farmers and manufactures products for other companies’ brands. It earns a processing margin over the milk price, highest on infant formula and specialised ingredients and lowest on commodity powders.
The company reports four streams. Advanced Nutrition covers infant-formula base powder and finished, canned formula made for brand owners. Ingredients covers milk powders, cream products and lactoferrin, a high-value protein. Consumer is mainly Dairyworks, a Christchurch cheese and butter business bought in 2020. Foodservice sells UHT cream to bakeries and beverage chains in China and South-East Asia.
Synlait has to pay a competitive milk price whatever its own margins are, because farmers can leave. For the 2025/26 season it paid a base price of NZ$9.69 per kilogram of milk solids, matching Fonterra, plus average incentives of 38 cents for meeting quality and sustainability standards, a total of NZ$10.07. Profit depends on turning that milk into products worth materially more than commodity powder, and on running plants close to capacity.
Because infant formula earns several times the margin of milk powder, a small change in formula volume moves the whole result. That sensitivity is the key to both the rise and the fall.
Who owns Synlait and how is it governed?
Bright Dairy holds 65.25% of Synlait and The a2 Milk Company about 19.8%, leaving roughly 15% with public investors on the NZX and ASX. The board is chaired by George Adams, and a director, Leon Fung, has been acting chief executive since mid-2026.
The register is unusual: the controlling shareholder is a Chinese state-linked dairy company, and the second-largest is Synlait’s most important customer. Each has interests beyond the share price. Bright values a New Zealand manufacturing base and has lent money as well as investing; a2 wants secure supply at Dunsandel while it brings its own plant into production. Minority investors, heavily diluted in 2024, have limited influence.
Leadership turnover has compounded the difficulty. Founder John Penno stepped back from the chief executive role in 2018. Leon Clements left in 2021 and Grant Watson in October 2024. Richard Wyeth, who had led the Chinese-owned Westland Milk Products, resigned in May 2026 after about a year, having steered the company through the asset sale. Three chief executives have departed in five years. Bright’s wider group also owns half of a major meat processor, as the Silver Fern Farms and Alliance story explains.
Why did Synlait become a share-market favourite?
Synlait became the contract manufacturer for a2 Platinum infant formula just as Chinese demand for that brand took off. Between 2016 and 2019 profits rose rapidly, and the shares climbed from the NZ$2.20 listing price to a peak of about NZ$13 in 2018.
The partnership looked ideal. The a2 Milk Company owned the brand and the consumer relationship; Synlait owned the registered factory, recruited farms with herds tested for the A2 protein and made the product under a long-term exclusive agreement. As a2’s sales through informal Chinese resellers soared, a story told in the a2 Milk Company article, Synlait’s Dunsandel plant ran full and each expansion paid for itself quickly.
Investors valued the company as a growth stock, not a processor. Management responded as growth companies do: it planned capacity for demand several years out and looked for new customers and categories to reduce its reliance on a single brand. The diversification was the right instinct. The way it was financed was the problem.
What went wrong?
Synlait committed to a second infant-formula plant, acquisitions and other projects, funded largely by borrowing, shortly before its main customer’s volumes fell. Demand then dropped, costs overran, and interest and depreciation on underused assets consumed the earnings.
The centrepiece was PΕkeno, in the Waikato, a new nutritional-powders plant costing several hundred million dollars, intended for multinational customers and commissioned around 2020. Alongside it came a liquid-milk plant at Dunsandel to supply a South Island supermarket group, the purchase of Dairyworks and a cheese business, and an expensive enterprise-software rollout. In 2019 Synlait raised NZ$180 million from retail investors through five-year bonds.
Then the pandemic closed borders. The daigou trade that had driven a2’s sales collapsed, a2 cut orders to work down inventory, and Synlait reported its first loss as a listed company in FY21. PΕkeno, which had secured one significant multinational customer, never ran near capacity. Relations with a2 soured into a formal dispute over whether a2 could end Synlait’s exclusive manufacturing rights.
By FY24 the loss had reached NZ$182.1 million after large write-downs. The bonds fell due in December 2024, bank covenants were breached and waived repeatedly, and a majority of farmer suppliers lodged notices of intention to cease supply, a precaution that would have let them leave after the notice period.
How did the Bright Dairy rescue work?
The rescue came in two steps during 2024: a NZ$130 million shareholder loan from Bright Dairy in July, then a NZ$217.8 million equity raise completed in October, tied to a bank refinancing and a settlement with a2. Bright’s stake rose from 39.01% to 65.25%.
The equity was placed at two prices. Bright subscribed NZ$185 million at 60 cents a share, a premium that reflected its move to control. The a2 Milk Company put in NZ$32.8 million at 43 cents, enough to maintain its 19.83% holding. The new money was roughly three times Synlait’s market value at the time. The equity raise, the a2 settlement and the bank refinancing were made conditional on one another, so shareholders had to approve all or none.
The chair was explicit about the alternative: without approval, Synlait would probably have had to cease trading and enter a formal insolvency process. Shareholders approved the package at a special meeting on 18 September 2024. The proceeds repaid bank debt and allowed the NZ$180 million of bonds to be redeemed on schedule in December, so retail bondholders were repaid in full while shareholders absorbed the losses.
The settlement with a2 ended the exclusivity dispute and reset the commercial terms, giving a2 freedom to manufacture elsewhere while keeping Synlait as a supplier. Most farmers subsequently withdrew their cease notices once the company’s survival was assured and supply premiums were improved.
Why did Synlait sell its North Island assets to Abbott?
The recapitalisation bought time but left too much debt and an underused plant. Selling PΕkeno and the Auckland sites to Abbott, the American healthcare group, for NZ$307 million (US$178 million) halved bank debt and returned Synlait to a single Canterbury base.
The sale completed on 2 April 2026. It covered the PΕkeno manufacturing facility, the leased blending and canning site and warehouse in Auckland, and inventory specific to Abbott: US$170 million for property, plant and equipment and about US$8 million for stock. Synlait received NZ$283.1 million at completion, with US$14 million held back against post-completion claims. Some NZ$200 million went straight to lenders, cutting committed bank facilities from NZ$400 million to NZ$200 million.
For Abbott, already the plant’s anchor customer, the purchase secured a nutritional-powders site with regulatory approvals at a price well below the cost of building one. For Synlait it meant accepting that the diversification strategy of 2018 had failed: the assets fetched less than had been invested in them. Wyeth called it an important turning point that would strengthen and simplify the business.
A geographical footnote often causes confusion. The a2 Milk Company also bought a plant at PΕkeno in 2025; that was the former Yashili factory, an entirely separate facility in the same town.
What do the 2025-2026 numbers show?
FY26, the year to 31 July 2026, was a year of two halves. Revenue was NZ$1.94 billion and the reported net loss NZ$75.4 million, but the second half produced a small profit of NZ$5.2 million after a first-half loss of NZ$80.6 million.
| Measure | First half FY26 | Second half FY26 |
|---|---|---|
| EBITDA | Loss of NZ$34.7 million | NZ$42.8 million |
| Net profit after tax | Loss of NZ$80.6 million | NZ$5.2 million |
| Product made in specification | 91% | 95% |
| Production plan attainment | 90% | 103% |
Management described the first half as a perfect storm. Manufacturing problems at Dunsandel in FY25 had run down customers’ inventories, forcing costly catch-up production; surplus milk at the seasonal peak had to be sold at poor prices; and whole-milk-powder prices fell sharply late in 2025. Net debt reached NZ$472.1 million at the half-year, before the Abbott proceeds arrived.
The second half shows what a stabilised business might earn. Operating measures improved markedly, with product made in specification averaging 99% in August 2026. For the full year, underlying EBITDA was NZ$46.3 million and the underlying loss NZ$21.6 million. Ingredients revenue fell 15% to NZ$574.7 million, Consumer revenue rose 32%, and Foodservice achieved its first full year of positive gross profit, at NZ$11 million. Bank facilities of NZ$320 million were refinanced and Bright’s shareholder loan was extended to July 2028. Synlait is also moving its balance date to 31 December, with a five-month transitional period to the end of 2026.
Who competes with Synlait?
Synlait competes for milk with Fonterra and other Canterbury processors, and for manufacturing contracts with infant-formula and ingredients plants in New Zealand, Australia and Europe. Its position is that of a mid-sized specialist between a giant co-operative and global nutrition companies.
In Canterbury, farmers can choose between Fonterra, Synlait, Open Country Dairy and Westland, and the supply premiums Synlait pays are the price of holding them. In contract manufacturing, brand owners increasingly prefer to own their registered plants, as both Abbott and a2 have now shown, which shrinks the pool of customers for an independent maker. Chinese domestic formula producers, favoured by regulators and consumers at home, have also taken share from imported product.
The areas where Synlait retains an edge are narrower: lactoferrin, where it is a significant global producer; UHT cream for Asian foodservice, where it competes with Fonterra; and Dairyworks’ strong position in New Zealand supermarket cheese, a market shaped by the retailers described in the article on the supermarket duopoly.
What are the main risks for Synlait now?
The main risks are loss of a2 volume as that customer shifts production to its own plant, thin margins on a still-indebted balance sheet, farmer supply and continued dependence on a controlling shareholder for funding.
Financially, net debt of NZ$215 million against underlying EBITDA of NZ$46.3 million is still high for a processor exposed to commodity swings, and the shareholder loan must eventually be repaid or converted. Minority shareholders face the possibility of further dilution, or of a takeover by Bright at a price they have little power to contest; delistings of this kind are part of the pattern described in the article on the NZX’s shrinking market.
Operational reliability is the third risk. The improvement in quality measures is recent, and the company is again without a permanent chief executive.
What can founders and CFOs learn from Synlait?
Synlait’s lesson is that the timing and funding of expansion matter more than its logic. Diversifying away from one customer was sensible; doing it with debt, at the top of the cycle, with assets that needed new customers to fill them, was not.
- Fund uncertain demand with equity. Synlait’s shares traded at a high multiple in 2018, when new capital would have been cheap. It borrowed instead, and issued equity in 2024 at a small fraction of that price.
- Do not build for customers not yet signed. PΕkeno had one anchor customer and capacity for several. Unused capacity carries interest and depreciation from the first day.
- Treat customer concentration as a balance-sheet risk. Dependence on one brand owner should have limited how much debt the company carried.
- Limit simultaneous projects. A new plant, acquisitions, a liquid-milk facility and a software overhaul at once stretched management as well as capital.
- Sell early. The Abbott sale came after the rescue; an earlier disposal, from a stronger position, would probably have realised more.
Further material on capital-raising decisions and growth pacing is collected in the Founders Hub.
What happens next for Synlait?
Synlait’s immediate tasks are to appoint a permanent chief executive, sustain the second-half operating performance through a full season and replace any infant-formula volume that moves to a2’s own plant. The forecast base milk price for 2026/27 is NZ$9.50.
The board’s stated aim is to rebuild the company with diversified revenue streams. In practice that means growing foodservice cream and lactoferrin, keeping Dairyworks performing and winning new nutrition customers for Dunsandel. The transitional reporting period to 31 December 2026 will give the first indication of whether the improvement holds through the spring milk peak, the point at which the first half of FY26 came unstuck.
Ownership is the larger uncertainty. Bright Dairy has now put in equity and debt well beyond its original investment and controls nearly two-thirds of the shares. It could keep Synlait listed as a recovering subsidiary, seek full ownership or, in time, sell to another strategic buyer. Whatever the outcome, Synlait’s period as an independent challenger is over; its future is as a Canterbury manufacturing platform inside a larger group’s plans.
Frequently Asked Questions
Who owns Synlait Milk?
Bright Dairy, a Shanghai-based dairy company controlled by the state-owned Bright Food group, owns 65.25% following the October 2024 recapitalisation. The a2 Milk Company owns about 19.8%. The remaining shares, roughly 15%, are held by institutional and retail investors and trade on the NZX and ASX.
Does Synlait still make a2 infant formula?
Yes. Synlait manufactures a2 Platinum infant formula at its Dunsandel plant in Canterbury under supply arrangements that were reset in 2024. However, a2 now owns its own plant at PΕkeno and has received Chinese regulatory approval to transition two China-label registrations there, so the volume made at Dunsandel may decline over time.
Did Synlait bondholders lose money?
No. The NZ$180 million of retail bonds issued in 2019 were repaid in full when they matured in December 2024, using funds from the shareholder loan, equity raise and bank refinancing. The losses fell on shareholders, whose holdings were heavily diluted by new shares issued at 43 and 60 cents.
Is Synlait profitable?
Not yet on a full-year basis. It reported a net loss after tax of NZ$75.4 million for the year to 31 July 2026. The second half was profitable, with net profit of NZ$5.2 million and EBITDA of NZ$42.8 million, which management presents as evidence of recovery after the sale of its North Island assets.
Discover more from Kurums | Business Intelligence
Subscribe to get the latest posts sent to your email.
